/
Psychiatry
Post-Traumatic Stress Disorder
31
Pipeline Programs↗
143
Active Trials↗
40
Companies Involved↗
Post-Traumatic Stress Disorder is a moderately active landscape with 31 programs across 40 companies. The most active players are Vanda Pharmaceuticals, Immedica Pharma AB, Lykos Therapeutics. 7 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical18
Phase 25
Phase 37
Approved
No programs
Analysis
Modality Breakdown
96%
Small molecule
27 of 28 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 28 classified programs, each share of the total. Modality classified for 90% of 31 pipeline programs.
Analysis
Trial Status
328
clinical trials
Completed133 · 41%
Recruiting83 · 25%
Not yet recruiting36 · 11%
Active, not recruiting18 · 5%
Unknown status18 · 5%
Terminated16 · 5%
Other24 · 7%
Clinical Trials
Trial Activity
328 trials
A Pilot Mechanistic RCT of Psilocybin With Mindfulness-based Therapy vs Support for Posttraumatic Stress Disorder (PTSD)
Recruiting·—·Phase 2·NCT07104916·30 enrolled
Page 1 of 22
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)